Overview

Apatinib Plus Docetaxel as 2nd Line Treatment in Patients With Advanced Lung Adenocarcinoma Harboring Wild-type EGFR

Status:
Unknown status

Trial end date:
2016-12-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to confirm the safety of Apatinib at a dose level up to 750 mg/d with standard therapy of docetaxel (60 mg/m²) in advanced lung adenocarcinoma patients harboring wild-type EGFR after failure of first line chemotherapy and to determine the recommended dose for the Phase II trial.

Phase:

Phase 1

Details

Lead Sponsor:

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Collaborator:

Jiangsu HengRui Medicine Co., Ltd.

Treatments:

Apatinib
Docetaxel